Dimensional Fund Advisors’s MoonLake Immunotherapeutics MLTX Stock Holding History

Dimensional Fund Advisors’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$411K	Sell	21,128 -5,179	-20%	-$93.9K	﹤0.01%	2987
2026 Q1	$490K	Sell	26,307 -157,245	-86%	-$2.6M	﹤0.01%	2945
2025 Q4	$2.42M	Buy	183,552 +172,550	+1,568%	+$2.04M	﹤0.01%	2698
2025 Q3	$78.9K	Sell	11,002 -41,717	-79%	-$2.17M	﹤0.01%	3213
2025 Q2	$2.49M	Sell	52,719 -775	-1%	-$31.6K	﹤0.01%	2708
2025 Q1	$2.09M	Sell	53,494 -10,890	-17%	-$469K	﹤0.01%	2715
2024 Q4	$3.49M	Buy	+64,384	New	+$3.29M	﹤0.01%	2640

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Dimensional Fund Advisors's MLTX Position: Q2 2026 in Review

Dimensional Fund Advisors reduced its MoonLake Immunotherapeutics (MLTX) stake by 20% in Q2 2026, selling an estimated $93.9K and leaving 21,128 shares worth $411K. The position accounts for ﹤0.01% of the portfolio, ranked #2987.

Dimensional Fund Advisors first reported a position in MLTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.49M in Q4 2024. 172 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Dimensional Fund Advisors held 21,128 shares of MoonLake Immunotherapeutics worth $411K as of Q2 2026.
Dimensional Fund Advisors sold 5,179 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $93.9K.
MoonLake Immunotherapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #2987 holding.
Dimensional Fund Advisors first reported a position in MoonLake Immunotherapeutics in Q4 2024 and has held it in 7 quarters since.
Dimensional Fund Advisors's MoonLake Immunotherapeutics position peaked at $3.49M in Q4 2024.
172 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.